The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
This study aimed to investigate the clinical characteristics and prognosis of Runt‐related transcription factor 1 (RUNX1) mutant acute myeloid leukemia (AML) patients by comparing the features of AML patients with or without RUNX1 mutation. We retrospectively analyzed 180 AML patients including 36 AML patients with mutant RUNX1(AML‐RUNX1mut) and 144 AML patients with wild‐type RUNX1(AML‐RUNX1wt) were...
According to the 2022 European LeukemiaNet, all acute myeloid leukemia (AML) cases with FLT3‐ITD mutations are now categorized as intermediate risk irrespective of the FLT3‐ITD allelic ratio or concurrent presence of NPM1 mutation. However, whether other next‐generation sequencing (NGS) comutation genes can add layers to FLT3‐ITD and whether the poor outcomes of FLT3‐ITD comutations can be overcome...